Table 5. Outcomes after repeat CRS/HIPEC for ovarian primaries.
| Author (citation) | Study type | Year | No. of patients | PCI | Median overall survival (months) | Median disease free interval (months) | Median follow-up (months) | Morbidity (grade 3 and 4) | Mortality | CC 0-1 |
|---|---|---|---|---|---|---|---|---|---|---|
| Bakrin et al. (53) | P | 2012 | 246 | 10.6 (mean) | 48.9 | 12.8 | NA | 11.6% | 0.4% | 92.2% |
| Di Giorgio et al. (55) | P | 2008 | 47 | 14.9 (mean) | 24.0 | 20.0 | NA | 21.3% | 4.2% | 100.0% |
| Raspagliesi et al. (56) | R | 2006 | 40 | NA | 41.4 | 23.9 | 26.1 | 5.0% | 0.0% | 100.0% |
| Cotte et al. (57) | P | 2007 | 81 | NA | 28.4 | 19.2 | 47.1 | 13.6% | 2.5% | 80.2% |
| Helm et al. (58) | R | 2007 | 18 | NA | 31.0 | NA | 16.2 (mean) | 100.0% | 5.6% | 83.3% |
| Pavlov et al. (59) | R | 2009 | 56 | 13.4 (mean) | 34.1 | 26.2 | 56.0 (mean) | 17.8% | 1.8% | 92.8% |
| Rufián et al. (60) | R | 2006 | 33 | NA | 48.0 | NA | NA | 36.0% | 0.0% | 85.0% |
| Deraco et al. (62) | R | 2012 | 56 | 15.2 (median) | 25.7 | 10.8 | 23.1 | 26.3% | 5.3% | 96.4% |
| Fagotti et al. (63) | R | 2011 | 41 | 6.0 (median) | 38.0 | 25.0 | 29.0 | 34.8% | 0.0% | 100.0% |
| Bakrin et al. (65) | R | 2013 | 566 | 8.5 (median) | 45.7 | NA | 40.0 | 31.3% | 0.8% | 92.7% |
CRS, cytoreductive surgery; HIPEC, hyperthermic intraperitoneal chemotherapy; P, prospective; R, retrospective; PCI, peritoneal cancer index; CC, completeness of cytoreduction; NA, not available.